Lieselotte Lemoine
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Lieselotte Lemoine has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Kurt Van der Speeten
Department of Surgical Oncology, Ziekenhuis Oost-Limburg, Genk, Belgium
3 shared publications Elsy Thijssen
Applied and Analytical Chemistry, Institute for Materials Research, Hasselt University, Diepenbeek, Belgium
2 shared publications- Jean-Paul Noben
Biomedical Research Institute and Transnational University Limburg, Hasselt University, Agoralaan D, 3590 Hasselt, Belgium
2 shared publications Kurt Van der Speeten
Department of Medicine and Life Sciences, Hasselt University, Hasselt, Belgium
2 shared publicationsPaul Sugarbaker
Center for Gastrointestinal Malignancies, MedStar Washington Hospital Center, Washington, DC, USA
2 shared publicationsRobert Carleer
Applied and Analytical Chemistry, Institute for Materials Research, Hasselt University, Diepenbeek, Belgium
2 shared publications
Latest Publications
- 5 March 2019
- Published by Wiley in Journal of Surgical Oncology
- Vol. 119 (7) , 999-1010
Body surface area‐based vs concentration‐based perioperative intraperitoneal chemotherapy after optimal cytoreductive surgery in colorectal peritoneal surface malignancy treatment: COBOX trial
Background and Objectives: Cytoreductive surgery (CRS) and hyperthermic intraperitoneal perioperative chemotherapy (HIPEC) are the standard of care for patients diagnosed with colorectal peritoneal surface malignancy (PSM). Despite a clearly defined standardization of CRS, a large variety of HIPEC modalities are still used in clinical practice.Methods: Body surface area (BSA)‐ and concentration‐based HIPEC protocols were clinically and pharmacologically evaluated in a randomized phase III clinical pilot trial. Oxaliplatin dose was 460 mg/m 2 (BSA‐based) in 2 L/m 2 carrier solution (concentration‐based). Platinum quantification was performed using a validated inductively coupled plasma mass spectrometry method. Three‐month morbidity, mortality, and health‐related quality of life (HRQOL) were assessed.Results: Thirty‐one patients were randomized to either BSA‐ or concentration‐based HIPEC. Toxicity and efficacy were higher (P < 0.001) in patients receiving concentration‐based HIPEC. There was no difference in pharmacologic advantage between the two groups. A higher drug concentration in the tumor nodule at the end of HIPEC was found in the HIPEC‐concentration group. There was no difference in major morbidity and mortality between the treatment groups. HRQOL was decreased 3 months postoperatively in the HIPEC‐concentration group.Conclusion: Concentration‐based chemotherapy delivers the drug in the most standardized way to the tumor nodule, resulting in increasing drug concentrations in the tumor nodule without increasing major morbidity.
- 5 March 2019
- Published by Wiley in Journal of Surgical Oncology
- Vol. 119 (7) , 999-1010
Body surface area‐based vs concentration‐based perioperative intraperitoneal chemotherapy after optimal cytoreductive surgery in colorectal peritoneal surface malignancy treatment: COBOX trial
Background and Objectives: Cytoreductive surgery (CRS) and hyperthermic intraperitoneal perioperative chemotherapy (HIPEC) are the standard of care for patients diagnosed with colorectal peritoneal surface malignancy (PSM). Despite a clearly defined standardization of CRS, a large variety of HIPEC modalities are still used in clinical practice.Methods: Body surface area (BSA)‐ and concentration‐based HIPEC protocols were clinically and pharmacologically evaluated in a randomized phase III clinical pilot trial. Oxaliplatin dose was 460 mg/m 2 (BSA‐based) in 2 L/m 2 carrier solution (concentration‐based). Platinum quantification was performed using a validated inductively coupled plasma mass spectrometry method. Three‐month morbidity, mortality, and health‐related quality of life (HRQOL) were assessed.Results: Thirty‐one patients were randomized to either BSA‐ or concentration‐based HIPEC. Toxicity and efficacy were higher (P < 0.001) in patients receiving concentration‐based HIPEC. There was no difference in pharmacologic advantage between the two groups. A higher drug concentration in the tumor nodule at the end of HIPEC was found in the HIPEC‐concentration group. There was no difference in major morbidity and mortality between the treatment groups. HRQOL was decreased 3 months postoperatively in the HIPEC‐concentration group.Conclusion: Concentration‐based chemotherapy delivers the drug in the most standardized way to the tumor nodule, resulting in increasing drug concentrations in the tumor nodule without increasing major morbidity.
- Open Access
- 15 February 2019
- Published by Impact Journals, LLC in Oncotarget
- Vol. 10 (14) , 1407-1424
Body surface area-based versus concentration-based intraperitoneal perioperative chemotherapy in a rat model of colorectal peritoneal surface malignancy: pharmacologic guidance towards standardization
Body surface area-based versus concentration-based intraperitoneal perioperative chemotherapy in a rat model of colorectal peritoneal surface malignancy: pharmacologic guidance towards standardization Body surface area-based versus concentration-based intraperitoneal perioperative chemotherapy in a rat model of colorectal peritoneal surface malignancy: pharmacologic guidance towards standardization
- 15 February 2019
- Published by Impact Journals, LLC in Oncotarget
- Vol. 10 (14) , 1407-1424
Open AccessBody surface area-based versus concentration-based intraperitoneal perioperative chemotherapy in a rat model of colorectal peritoneal surface malignancy: pharmacologic guidance towards standardization
Body surface area-based versus concentration-based intraperitoneal perioperative chemotherapy in a rat model of colorectal peritoneal surface malignancy: pharmacologic guidance towards standardization Body surface area-based versus concentration-based intraperitoneal perioperative chemotherapy in a rat model of colorectal peritoneal surface malignancy: pharmacologic guidance towards standardization
- 27 August 2018
- Published by Taylor & Francis in Journal of Liquid Chromatography & Related Technologies
- Vol. 41 (13-14) , 839-848
A validated high performance liquid chromatography – diode array detector method for the quantification of mitomycin C in plasma, peritoneal fluid and urine
Mitomycin C (MMC) is a quinone-containing alkylating agent, that has been extensively studied in preclinical and clinical work due to its antitumor activity. A thoroughly validated high performance liquid chromatography-diode array detector method is provided to quantify MMC in plasma, peritoneal fluid and urine. Porfiromycin served as internal standard. The mobile phase for the plasma, peritoneal fluid and urine analysis consisted of 27% MeOH and 73% 20 mM ammoniumacetate buffer (pH 6.5) and 9% ACN and 91% 20 mM phosphate buffer (pH 6.5) respectively. The residue from 100 µL ACN deproteinated plasma was dissolved in 250 µL mobile phase. Peritoneal fluid and urine were diluted 10-fold in their respective mobile phases. UV detection was performed at 365 nm. Quantification of MMC was achieved over a linear range of 0.05–5 µg/mL and 5–50 µg/mL in plasma; 0.1–5 µg/mL and 5–100 µg/mL in peritoneal fluid; 0.25–5 µg/mL and 5–100 µg/mL in urine. The limit of quantification was 0.05 µg/mL in plasma, 0.1 µg/mL in peritoneal fluid and 0.25 µg/mL in urine. The method was further validated for selectivity, specificity, inter- and intraday precision and accuracy (≤15%), extraction recovery and stability. MMC remains stable in the different biofluids for 20 days (short-term stability) at 4 °C, −27 °C and −80 °C and for 80 days (long-term stability) at −80 °C. Graphical Abstract
- 27 August 2018
- Published by Taylor & Francis in Journal of Liquid Chromatography & Related Technologies
- Vol. 41 (13-14) , 839-848
A validated high performance liquid chromatography – diode array detector method for the quantification of mitomycin C in plasma, peritoneal fluid and urine
Mitomycin C (MMC) is a quinone-containing alkylating agent, that has been extensively studied in preclinical and clinical work due to its antitumor activity. A thoroughly validated high performance liquid chromatography-diode array detector method is provided to quantify MMC in plasma, peritoneal fluid and urine. Porfiromycin served as internal standard. The mobile phase for the plasma, peritoneal fluid and urine analysis consisted of 27% MeOH and 73% 20 mM ammoniumacetate buffer (pH 6.5) and 9% ACN and 91% 20 mM phosphate buffer (pH 6.5) respectively. The residue from 100 µL ACN deproteinated plasma was dissolved in 250 µL mobile phase. Peritoneal fluid and urine were diluted 10-fold in their respective mobile phases. UV detection was performed at 365 nm. Quantification of MMC was achieved over a linear range of 0.05–5 µg/mL and 5–50 µg/mL in plasma; 0.1–5 µg/mL and 5–100 µg/mL in peritoneal fluid; 0.25–5 µg/mL and 5–100 µg/mL in urine. The limit of quantification was 0.05 µg/mL in plasma, 0.1 µg/mL in peritoneal fluid and 0.25 µg/mL in urine. The method was further validated for selectivity, specificity, inter- and intraday precision and accuracy (≤15%), extraction recovery and stability. MMC remains stable in the different biofluids for 20 days (short-term stability) at 4 °C, −27 °C and −80 °C and for 80 days (long-term stability) at −80 °C. Graphical Abstract
- 1 January 2018
- Published by Springer Nature
- p. 119-141
Applikation von IPC, HIPEC und PIPAC
- 30 November 2017
- Published by Springer Nature
- p. 79-102
HIPEC Methodology, Comparison of Techniques, and Drug Regimens: Is There a Need for Standardization?
- 30 November 2017
- Published by Springer Nature
- p. 79-102
HIPEC Methodology, Comparison of Techniques, and Drug Regimens: Is There a Need for Standardization?